These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9818471)

  • 41. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
    Reiser M; Josting A; Draube A; Mapara MY; Scheid C; Chemnitz J; Tesch H; Wolf J; Diehl V; Söhngen D; Engert A
    Bone Marrow Transplant; 1999 Jun; 23(12):1223-8. PubMed ID: 10414907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
    Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
    Bone Marrow Transplant; 2002 Feb; 29(4):285-90. PubMed ID: 11896424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
    Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B
    Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C; Cuttica A; Vitolo U; Liberati M; Di Nicola M; Cortelazzo S; Rosato R; Rosanelli C; Di Renzo N; Musso M; Pavone E; Santini G; Pescarollo A; De Crescenzo A; Federico M; Gallamini A; Pregno P; Romano R; Coser P; Gallo E; Boccadoro M; Barbui T; Pileri A; Gianni AM; Levis A
    Cancer; 2003 Jun; 97(11):2748-59. PubMed ID: 12767087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
    Donato ML; Gershenson D; Ippoliti C; Wharton JT; Bast RC; Aleman A; Anderlini P; Gajewski JG; Giralt S; Molldrem J; Ueno N; Lauppe J; Korbling M; Boyer J; Bodurka-Bevers D; Bevers M; Burke T; Freedman R; Levenback C; Wolf J; Champlin RE
    Bone Marrow Transplant; 2000 Jun; 25(11):1137-40. PubMed ID: 10849525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
    Bonfante V; Viviani S; Devizzi L; Di Russo A; Di Nicola M; Magni M; Matteucci P; Grisanti S; Valagussa P; Bonadonna G; Gianni AM
    Eur J Haematol Suppl; 2001 Jul; 64():51-5. PubMed ID: 11486403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
    Lazar AD; Shpilberg O; Shaklai M; Bairey O
    Isr Med Assoc J; 2009 Jan; 11(1):16-22. PubMed ID: 19344007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
    Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
    Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
    Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
    Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ifosfamide in the treatment of non-Hodgkin's lymphoma.
    Pohlman B
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):27-32. PubMed ID: 8677445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
    Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
    Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
    Emmanouilides C; Lill M; Telatar M; Rosenfelt F; Grody W; Territo M; Rosen P
    Clin Lymphoma; 2002 Sep; 3(2):111-6. PubMed ID: 12435284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
    Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
    Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
    Cabanillas F; Rodriguez MA
    Semin Hematol; 1994 Apr; 31(2 Suppl 3):30. PubMed ID: 8073305
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
    Dincol D; Buyukcelik A; Dogan M; Akbulut H; Samur M; Demirkazik A; Senler FC; Onur H; Icli F
    Med Oncol; 2010 Sep; 27(3):942-5. PubMed ID: 19787462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peripheral blood stem cell mobilization following salvage chemotherapy (IAPVP-16) plus granulocyte colony-stimulating factor and autografting for non-Hodgkin's lymphoma.
    Martínez C; Mateu R; Sureda A; Brunet S; Amill B; Madoz P; Portos JM; Subirà M; García-López J; Domingo-Albós A
    Transplant Proc; 1995 Aug; 27(4):2355-6. PubMed ID: 7544503
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
    Weaver CH; Zhen B; Buckner CD
    Bone Marrow Transplant; 1998 Jun; 21(11):1169-70. PubMed ID: 9645585
    [No Abstract]   [Full Text] [Related]  

  • 60. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
    Aurer I; Nemet D; Mitrović Z; Dujmović D; Bašić-Kinda S; Radman I; Sertić D; Šantek F; Kralik M; Dotlić S; Mazić S; Labar B
    Ann Hematol; 2016 Jun; 95(7):1129-36. PubMed ID: 27103009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.